About Evozyne
Evozyne is a company based in Chicago (United States) founded in 2020 by Andrew Ferguson and Rama Ranganathan. Evozyne has raised $144.37 million across 4 funding rounds from investors including Fidelity Investments, Paragon Biosciences and Orbimed. Evozyne offers products and services including AI Protein Design Platform and Partnership Pipeline. Evozyne operates in a competitive market with competitors including Nimbus Therapeutics, Cradle, EvolutionaryScale, Profluent Bio and Frontier Medicines, among others.
- Headquarter Chicago, United States
- Founders Andrew Ferguson, Rama Ranganathan
- SectorsHealthcare
- Website evozyne.com
- Social LinkedIn
- Legal Name Evozyne, Inc.
- Total Equity Funding$144.37M (USD)
in 4 rounds
- Latest Funding Round$81M (USD), Series B
Sep 2023
- InvestorsFidelity Investments
& 4 more
Products & Services of Evozyne
Evozyne offers a comprehensive portfolio of products and services, including AI Protein Design Platform and Partnership Pipeline.
Platform that designs novel proteins using Generative AI for medical applications
System for advancing protein therapeutics through investor and advisor partnerships
Funding Insights of Evozyne
Evozyne has successfully raised a total of $144.37M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $81 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $144.37M
- Total Rounds 4
- Last Round Series B — $81M
- First Round $9.18M
(Apr 2020)
- Investors Count 5
All 4 funding rounds of Evozyne with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2023 | – | Debt – Conventional | – | – | – |
| Sep 2023 | $81M | Series B | – | Fidelity Investments, Orbimed | |
| Apr 2021 | $54.18M | Series B | – | – | – |
| Apr 2020 | $9.18M | Series A | – | – | – |
5 investors in total: 5 institutional.
Investors in Evozyne
Evozyne has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Paragon Biosciences and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Private equity firm | – | valorep.com | Chicago, United States | |
Venture capital arm of Nvidia | – | nventures.ai | Santa Clara, United States | |
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
Advisory services are provided to healthcare companies. | 2010 | paragonbiosci.com | Chicago, United States |
Investor details for Evozyne
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Evozyne
10 people are tracked at Evozyne (3 in leadership, 7 in board & advisors).
| Name | Role | Group |
|---|---|---|
Andrew Ferguson | Co-Founder | Leadership |
Rama Ranganathan | Co-Founder & CSO | Leadership |
Mike Gamson | Vice Chairman Of The Board, Former CEO | Leadership |
Polly Fordyce | Scientific Advisor | Board & advisors |
John Kuriyan | Scientific Advisor | Board & advisors |
Matthew Tirrell | Chair | Board & advisors |
Donald Hilvert | Scientific Advisor | Board & advisors |
Patrick Wilson | Scientific Advisor | Board & advisors |
Stephen L. Mayo | Scientific Advisor | Board & advisors |
Alanna Schepartz | Scientific Advisor | Board & advisors |
Complete people profiles for Evozyne
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Evozyne
3 dated milestones of Evozyne across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Evozyne is founded.
- Funding First funding round of $9.2M.
- Funding Latest funding round, Series B, of $81.0M.
Competitors of Evozyne
Evozyne operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Cradle, EvolutionaryScale, Profluent Bio and Frontier Medicines, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| cradle.bio | 2021 | Delft, Netherlands | $102.71M | – | Chemoproteomics solutions are provided for protein design and development. | |
| evolutionaryscale.ai | 2023 | New York, United States | $142M | – | Provider of an AI models for protein design | |
| profluent.bio | 2022 | Berkeley, United States | $44M | – | An AI-based protein design platform is provided for drug discovery. | |
| frontiermeds.com | 2018 | San Francisco, United States | $235.5M | 115 | Bioinformatics platform is developed for drug discovery and chemoproteomics. | |
| eikontx.com | 2019 | Hayward, United States | $1.16B | – | Protein dynamics are tracked and measured for drug discovery processes. | |
| entactbio.com | 2022 | Watertown, United States | $120.9M | – | Drugs are developed to enhance functions of beneficial proteins. |
Detailed competitors of Evozyne
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Evozyne
The website of Evozyne (evozyne.com) receives about 4.3K visits a month.
- Monthly visits4.3K
▲ 76.3% vs previous month
Latest news on Evozyne
Complete news archive for Evozyne
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Evozyne
10 companies that operate in the same segment as Evozyne (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Evozyne
Evozyne was founded in 2020.
Evozyne is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Evozyne is a funded company, having raised a total of $144.37M across 4 funding rounds to date. The company's 1st funding round was a Series A of $9.18M, raised on Apr 2020.
Evozyne has developed novel proteins using protein engineering technology. The company uses machine learning, statistical techniques with high throughput gene synthesis and screening technology to build predictive models of sequence-function relationships for a family of proteins for synthesis, and characterizing of the proteins.
Evozyne's top competitors include Nimbus Therapeutics, Cradle and Profluent Bio.
Evozyne offers AI Protein Design Platform and Partnership Pipeline.
Evozyne has 5 investors. Key investors include Fidelity Investments, Paragon Biosciences, Orbimed, Valor Equity Partners, and NVentures.
Evozyne operates through Evozyne, Inc..